CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data in
 

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

More...